Status:
UNKNOWN
Voriconazole-Induced QT Interval Prolongation: A Prospective Study
Lead Sponsor:
Rabin Medical Center
Conditions:
Voriconazole Induced QT Interval Prolongation
Eligibility:
All Genders
Up to 20 years
Brief Summary
The antifungal voriconazole is effective for the treatment of invasive fungal infections in immunocompromised patients. A serious adverse reaction is QT interval prolongation, which may precede life-t...
Eligibility Criteria
Inclusion
- oral or IV treatment with voriconazole
Exclusion
- No data prior to initiation of voriconazole treatment on QT interval (baseline ECG)
- Renal insufficiency or dialysis treatment
Key Trial Info
Start Date :
October 31 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04502355
Start Date
October 31 2016
End Date
December 31 2020
Last Update
August 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schneider childrens medical center of Isreal
Petah Tikva, Israel